Keynote Presentation: Cannabinoid Hyperemesis Syndrome: Investigating the Mystery with Live Q&A скачать в хорошем качестве

Keynote Presentation: Cannabinoid Hyperemesis Syndrome: Investigating the Mystery with Live Q&A

Presented By: Ethan Russo, MD Speaker Biography: Ethan Russo, MD, is a board-certified child and adult neurologist(1987), psychopharmacologist, and Founder/CEO of CReDO Science. He is also Chief Medical Officer to Andira Pharmaceuticals, Senior Medical Advisor to Canurta and Medical Director of Breeder’s Best. He was Director of R&D for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®. He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments as Adjunct Associate Professor, Department of Pharmaceutical Sciences, University of Montana and Clinical Assistant Professor, University of Washington School of Medicine. He is author/editor of seven books and has published over than 60 peer-reviewed articles. He was a 1973 graduate of the University of Pennsylvania (Psychology), University of Massachusetts Medical School (1978), and trained in pediatrics (Phoenix Hospitals Affiliated Pediatrics Program)(1978-1980) and pediatric and adult neurology at the University of Washington (1980-1983). Webinar: Keynote Presentation: Cannabinoid Hyperemesis Syndrome: Investigating the Mystery with Live Q&A Webinar Abstract: Cannabinoid hyperemesis syndrome (CHS) is a constellation of intractable vomiting, abdominal pain and hot bathing behavior that solely occurs in the context of heavy chronic use of THC-predominant cannabis or CB1 agonists. It is associated with frequent emergency visits with high associated expense ($30-90K USD). Considerable morbidity and even some fatalities have been reported. The definitive treatment is abstention from cannabis usage, but parenteral haloperidol and cutaneous application of capsaicin ointment can provide symptomatic relief. The etiology of CHS may relate to biphasic dose responses to THC, a paradoxical shift of THC from partial agonist to antagonist of CB1, or effects on the TRPV1 receptor. After ethics approval, a screening questionnaire was posted online. Kits were sent to assess the DNA of patients fulfilling CHS criteria to assess single nucleotide polymorphisms (SNPs) or other mutations as compared to controls without this disorder. 585 people took the survey. Most were high frequency users of cannabis flower or concentrates (93%), using multiple grams/d of THC-predominant material. 15.6% carried diagnoses of cannabis dependency of addiction, and 56.6% experienced withdrawal symptoms. 87.7% of patients with diagnosis or symptoms indicative of CHS were improved after cannabis cessation, most suffering recurrence rapidly after resumption of use. 40 patients returned kits for genomic analysis, 28 CHS patients who carried formal CHS diagnosis and had consistent symptom profiles, and 12 controls with heavy cannabis usage and no CHS symptoms. Findings included mutations in genes coding COMT (p=0.0009), TRPV1 (p=0.021), CYP2C9 (p=0.0414), DRD2 (p=0.027) and ABCA1 (p=0.008), relating to CHS pathophysiology and clinical manifestations. These results shed light on CHS pathophysiology and additional risk factors of this important emerging public health issue. Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (https://www.labroots.com/) 2. Watch the webinar on YouTube or on the Labroots Website (https://www.labroots.com/ms/webinar/k...) 3. Click Here to get your PACE credits (Expiration date – April 17, 2026): (https://www.labroots.com/credit/pace-... Labroots on Social: Facebook:   / labrootsinc   Twitter:   / labroots   LinkedIn:   / labroots   Instagram:   / labrootsinc   Pinterest:   / labroots   SnapChat: labroots_inc